Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2019 - 2025)

BridgeBio Pharma's Net Income towards Common Stockholders history spans 7 years, with the latest figure at -$192.9 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 27.24% year-over-year to -$192.9 million; the TTM value through Dec 2025 reached -$724.9 million, down 35.31%, while the annual FY2025 figure was -$724.9 million, 35.31% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$192.9 million at BridgeBio Pharma, down from -$182.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$9.9 million in Q2 2022 and bottomed at -$265.0 million in Q4 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$160.0 million (2023), against an average of -$147.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders surged 89.77% in 2022 before it crashed 1502.06% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$147.2 million in 2021, then grew by 6.51% to -$137.6 million in 2022, then fell by 22.21% to -$168.1 million in 2023, then plummeted by 57.63% to -$265.0 million in 2024, then grew by 27.24% to -$192.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Net Income towards Common Stockholders are -$192.9 million (Q4 2025), -$182.7 million (Q3 2025), and -$181.9 million (Q2 2025).